Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00995514 · ClinicalTrials.gov registry record
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study
A clinical trial, sponsored by Medco Health Solutions.
- Terminated
- Registry status
- 4,471
- Enrollment target
NCT00995514 is a clinical trial that was terminated before completion, run by Medco Health Solutions. The registered enrollment target is 4,471 participants.
The verdict
NCT00995514 was terminated before completion, sponsored by Medco Health Solutions.
- TERMINATED
- Registry status
- 4,471 participants
- Enrollment target
Study Summary
The primary objective of this trial is to demonstrate the non-inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited to the estimated 70% of the population that are CYP2C19 extensive metabolizers. This protocol will examine the comparative effectiveness of these two strategies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,471 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00995514
The ClinicalTrials.gov registry entry for NCT00995514 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 4,471 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medco Health Solutions, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00995514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00995514 about?
NCT00995514 is a clinical study titled "Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study". The primary objective of this trial is to demonstrate the non-inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited to the estimated 70% of the population that are CYP2C19 extensive metabolizers. This protocol will ex...
What is the current status of trial NCT00995514?
This trial is currently terminated. The enrollment target is 4,471 participants. The study started on 2009-10. Estimated completion is 2012-05.
Who is sponsoring clinical trial NCT00995514?
This trial is sponsored by Medco Health Solutions, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.